Trial Profile

A Phase II Trial of the MEK Inhibitor Mirdametinib in Histiocytic Disorders

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 27 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Mirdametinib (Primary)
Indications Langerhans cell histiocytosis
Focus Therapeutic Use

Most Recent Events

17 Jan 2024 Planned End Date changed from 1 Dec 2030 to 1 Mar 2031.
17 Jan 2024 Planned primary completion date changed from 1 Dec 2029 to 1 Mar 2030.
17 Jan 2024 Planned initiation date changed from 1 Dec 2023 to 1 Mar 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com